Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
Public ClinicalTrials.gov record NCT02324335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug/radiation regimens used to treat cancer. This study examines the investigational drug brilacidin and its possible application in prevention of oral mucositis in patients undergoing chemoradiation for treatment of head and neck cancer.
Study identification
- NCT ID
- NCT02324335
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 14, 2014 (Actual)
- Primary completion
- Oct 25, 2017 (Actual)
- Completion
- Nov 22, 2017 (Actual)
- Last update posted
- Jan 16, 2019
2014 – 2017
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Gilbert | Arizona | 85234 | — |
| Not listed | Lakeland | Florida | 33805 | — |
| Not listed | Columbus | Georgia | 31904 | — |
| Not listed | Louisville | Kentucky | 40207 | — |
| Not listed | Shreveport | Louisiana | 71103 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Albuquerque | New Mexico | 87131 | — |
| Not listed | Cheektowaga | New York | 14225 | — |
| Not listed | Poughkeepsie | New York | 11794 | — |
| Not listed | Rochester | New York | 14642 | — |
| Not listed | Stony Brook | New York | 11794 | — |
| Not listed | Cleveland | Ohio | 44106 | — |
| Not listed | Toledo | Ohio | 43623 | — |
| Not listed | Philadelphia | Pennsylvania | 19140 | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | Milwaukee | Wisconsin | 53211 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02324335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 16, 2019 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02324335 live on ClinicalTrials.gov.